Dangerous Obesity Drug Gets the Boot
On 21 January 2010, the Medicines and Healthcare products Regulatory Agency (MHRA) announced the suspension of the obesity drug sibutramine which also goes by the names Reductil and Meridia, in the UK and the rest of Europe.
The suspension of Reductil follows a review by the European Medicines Agency (EMA) which conducted a trial with 10,000 participants and found the risks of taking Reductil far outweigh the benefits. In fact, that’s a massive understatement, as it’s been found to increase the risk of non-fatal heart attacks and strokes… not a trade-off I for one would like to make!